Heparin-binding epidermal growth factor (EGF)-like growth factor (HBEGF) is a ligand for the EGF receptor (EGFR), one of the most commonly amplified receptor tyrosine kinases (RTKs) in glioblastoma (GBM). While HBEGF has been found to be expressed in a subset of malignant gliomas, its sufficiency for glioma initiation has not been evaluated. In this study, we demonstrate that HBEGF can initiate GBM in mice in the context of Ink4a/Arf and Pten loss, and that these tumors are similar to the classical GBM subtype observed in patients. Isogenic astrocytes from these mice showed activation not only of Egfr but also the RTK Axl in response to HBEGF stimulation. Deletion of either Egfr or Axl decreased the tumorigenic properties of HBEGF-transformed cells; however, only EGFR was able to rescue the phenotype in cells lacking both RTKs indicating that Egfr is required for activation of Axl in this context. Silencing of HBEGF in vivo resulted in tumor regression and significantly increased survival, suggesting that HBEGF may be a clinically relevant target.
INTRODUCTION
Malignant gliomas, including anaplastic astrocytomas and glioblastomas (GBM), are aggressive tumors that confer a poor prognosis upon diagnosis. 1, 2 Anaplastic astrocytomas are characterized by high mitotic activity and cytological atypia. GBMs retain the features of lower grade gliomas but additionally present with microvascular proliferation and/or pseudopalisading necrosis. 1 With treatment, which consists of surgery, radiotherapy and chemotherapy, the average survival for patients diagnosed with GBM is~14 months. 2 Therefore, there is a strong need to understand the mechanisms underlying malignant glioma initiation and maintenance such that new therapies can be developed.
GBM was the first cancer to be systematically analyzed by The Cancer Genome Atlas (TCGA) network. 3, 4 Sequencing of these tumors revealed alterations in three core pathways. The receptor tyrosine kinase (RTK)/RAS/phosphatidylinositol-3-kinase (PI3K) pathway was altered in 88%, the retinoblastoma (RB) pathway was altered in 78% and the p53 pathway was altered in 87% of samples. 3, 4 In the RTK/RAS/PI3K axis, the most common alterations were mutation or amplification of epidermal growth factor receptor (EGFR) and homozygous deletion of phosphatase and tensin homolog deleted on chromosome ten (PTEN). In the p53 and RB pathways, the most common lesion was homozygous deletion of cyclin-dependent kinase 2 A, which encodes both p16 INK4a and p14 ARF . EGFR amplified tumors, which account for 65% of GBMs, are often associated with increased expression of EGFR ligands including heparin-binding EGF-like growth factor (HBEGF). [5] [6] [7] HBEGF has been associated with the progression of many solid tumors including breast, pancreatic and ovarian. [8] [9] [10] In up to 40% of malignant gliomas, HBEGF has been shown to be coexpressed with EGFR by immunohistochemistry. 5, 7 Additionally, HBEGF mRNA transcripts were two-to fivefold greater in GBM compared with normal brain tissue. 5 HBEGF mRNA has been detected in the brainstem at E14, as well as in the developing cortical plate, hippocampus, thalamus and cerebellar Purkinje cells, suggestive of a role in neuronal and glial maturation. 11 Additionally, administration of HBEGF in young and adult mice significantly increased the proliferation of neural progenitor cells in the subventricular zone and hippocampal dentate subgranular zone. 12 HBEGF also stimulates proliferation of neural progenitor cells and astrocytes via activation of EGFR and the MAPK/ERK pathway. 13 HBEGF is mitogenic in human glioma cell lines and this activity can be blocked with HBEGF-neutralizing antibodies. 5, 7 In addition to activation of EGFR, HBEGF has been shown to have other pleiotropic properties in bladder cancer including induction of matrix metalloproteinase-9 and vascular endothelial growth factor expression, which allows for tumor invasion and proliferation. 14 In chicken fibroblasts, expression of HBEGF induces transformation. 15 In U251 glioma cells, expression of EGFRvIII, the most common variant of EGFR, induces expression of HBEGF. Moreover, silencing of HBEGF decreases EGFRvIII tumorigenicity in this context. 7, 16 However, the ability of HBEGF to promote transformation in astrocytes in vitro and induce or sustain gliomas in vivo has not been assessed.
In the current study, we used the well-established RCAS/TVA glioma mouse model to assess the role of HBEGF in gliomagenesis and maintenance in vivo. Tumors generated using this model arise from a small number of cells within a normal microenvironment, which mimics the human disease. Furthermore, mammalian cells ectopically expressing the viral receptor TVA can be infected with several different RCAS viruses to allow the determination of the minimal components required for tumorigenesis. We demonstrate that HBEGF can promote tumor development in the context of either Ink4a/Arf and/or Pten loss. Furthermore, suppression of HBEGF expression in tumor-bearing mice resulted in significantly increased survival, which suggests it may be a relevant target for therapy. Interestingly, we discovered that HBEGF signals through both Egfr and Axl in this context. While AXL has been implicated in GBM formation, it has not been previously reported to have a role in HBEGF signal transduction. 17, 18 
RESULTS

Overexpression of HBEGF correlates with decreased survival in GBM patients
To assess the effect of ligand overexpression on patient survival, we compared the median survival among cohorts of patients whose tumors overexpressed one of seven different EGFR ligands. We observed that patients harboring malignant gliomas that overexpressed HBEGF had a median survival of only 7.4 months, which was significantly shorter than the median survival of 13.6 months in patients with malignant gliomas that did not overexpress HBEGF ( Supplementary Table S1 ). This suggests that overexpression of HBEGF confers a worse prognosis in these patients. Further analysis of the relative expression levels of these EGFR ligands revealed that HBEGF is expressed at significantly higher levels in these tumors ( Supplementary Figures S1a and b ).
HBEGF promotes anchorage-independent growth
Although HBEGF has been shown to increase the proliferation of human glioma cells in vitro, 5 little is known about the role of this ligand in the biology of malignant gliomas. To evaluate the role(s) of specific genes in glioma initiation, progression and maintenance, we and others have used a somatic-cell gene delivery method based on the RCAS/TVA retroviral vector system and successfully induced malignant gliomas in vivo. 19, 20 Using this established model system, we initially assessed the ability of HBEGF to transform primary astrocytes derived from Nestin-TVA; Ink4a/Arf lox/lox mice. These astrocytes were infected with RCAS-Cre alone or in combination with either RCAS-HBEGF and/or RCAS-EGFR. Following confirmation of HBEGF and EGFR expression ( Figure 1a ), the ability of the astrocytes to grow in an anchorageindependent manner was assessed by growth in soft agar. These astrocytes were immortalized by deletion of Ink4a/Arf to allow for ease of growth in culture, but they are not transformed as evidenced by the lack of colonies detected in the Nestin-TVA; Ink4a/Arf lox/lox astrocytes without EGFR or HBEGF infection ( Figure 1b ). Anchorage-independent growth was detected in astrocytes expressing HBEGF (P o 0.0001). While colonies were also observed when EGFR was expressed in the absence of HBEGF, they were significantly fewer in number than was observed in astrocytes expressing HBEGF (P = 0.01). No significant difference in colony number was observed between astrocytes expressing HBEGF alone or coexpressing EGFR (P = 0.2). EGFR activity was confirmed by adding known quantities of HBEGF to astrocytes either without (− ) or with exogenous receptor (EGFR; Figure 1c ). Dose-dependent phosphorylation of EGFR (Y1068), as well as activation of downstream targets including Akt (S473) and Erk1/2 (T202/204), was observed. As expected, higher levels of phosphorylated EGFR were observed in cells expressing exogenous EGFR. For comparison with other EGFR ligands, the ability of AREG and EREG to promote the growth of immortal astrocytes in soft agar was also assessed. While both of these ligands conferred anchorage-independent growth, HBEGF was a more potent inducer of colony formation in this context (Supplementary Figure S1c ).
Expression of HBEGF results in reduced survival in vivo in the context of Ink4a/Arf or Pten loss To evaluate the effect of HBEGF expression in nestin-expressing cells in vivo, we used Nestin-TVA;Ink4a/Arf lox/lox mice and generated both Nestin-TVA;Pten lox/lox and Nestin-TVA;Ink4a/Arf lox/lox ; Pten lox/lox mice. Exons 2 and 3 of the Ink4a/Arf locus are flanked by LoxP sites such that in the absence of Cre, these mice express normal levels of p16 INK4a and p19 ARF . Cre-mediated excision renders both p16 Ink4a and p19 Arf non-functional. 21 Exon 5 of the Pten locus is flanked by LoxP sites such that in the absence of Cre, these mice express normal levels of Pten. Cre-mediated excision eliminates exon 5, which encodes for a region of Pten that is essential for its phosphatase activity. 22 Delivery of either HBEGF or Cre alone did not result in a decrease in survival within the experimental timepoint of 16 weeks in any of the strains evaluated ( Figures 2a and b and Supplementary Table S2 ). Intracranial delivery of viruses containing HBEGF and Cre in Nestin-TVA;Ink4a/ Arf lox/lox mice resulted in a mean survival of 68.5 ±21.2 days, whereas expression of HBEGF and Cre resulted in a mean survival of 56.1 ± 11.8 days in Nestin-TVA;Pten lox/lox mice and 28.7 ± 2.3 days in Nestin-TVA;Ink4a/Arf lox/lox ;Pten lox/lox mice. A significant difference in mean survival was observed between each of these cohorts when compared with either the HBEGF or Cre alone cohorts (P o0.05; Figure 2a and Supplementary Table S2 ).
Addition of exogenous EGFR does not enhance the effect of HBEGF in vivo
Although a significant difference was not observed in soft-agar colony formation when exogenous EGFR was coexpressed with HBEGF, we evaluated the effect of exogenous EGFR in vivo by delivering RCAS-EGFR along with RCAS-Cre and RCAS-HBEGF in Nestin-TVA;Ink4a/Arf lox/lox , Nestin-TVA;Pten lox/lox and Nestin-TVA; Ink4a/Arf lox/lox ;Pten lox/lox mice. The median survival for these cohorts was not significantly different than cohorts lacking exogenous EGFR (P40.1; Figures 2a and b and Supplementary  Table S2 ). Data are represented as mean ± s.e.m. Using a two-tailed Student's t-test, the number of colonies formed were compared with control and statistical significance is shown by the following key: ***P o0.0005 with not significant (NS) denoting P40.05. (c) Western blot analysis of downstream effector pathways in Ink4a/Arf lox/lox astrocytes expressing either endogenous ( − ) or exogenous (EGFR). HBEGF was added to serum-free media at two different concentrations (0.5 and 5.0 ng/ml).
HBEGF expressing mouse tumors histologically resemble human malignant gliomas
Brain sections were examined following necropsy and were scored as no tumor, low-grade tumor or high-grade tumor based on histological features apparent on hematoxylin and eosin (H&E) sections. Low-grade tumors demonstrated single-cell infiltration with nuclear atypia including hyperchromasia and pleomorphism, whereas high-grade tumors also exhibited mitotic figures, vascular proliferation and areas of pseudopalisading necrosis (Figures 3a  and b ). Seventy-five percent of the tumors were high grade when both Ink4a/Arf and Pten were lost, whereas only 36% were high grade with Pten loss alone. No high-grade tumors were observed with loss of Ink4a/Arf alone, but 45% of mice developed low-grade tumors in this cohort. No tumors were observed in brain sections of mice injected with viruses carrying only HBEGF or Cre (Figure 3c and Supplementary Table S2 ). Virally delivered HBEGF was detected in all tumors using immunohistochemistry (IHC) ( Figure 3a ). Loss of Ink4a/Arf and Pten were also confirmed with immunohistochemistry (Supplementary Figure S2 ). All tumors also expressed the astrocyte marker glial fibrillary acidic protein and the neural progenitor cell marker nestin, although less staining was observed in the tumors with loss of Ink4a/Arf alone ( Figure 3a ). Assessment by IHC of the proliferative marker Ki67 showed that tumors lacking Pten or Pten and Ink4a/Arf were more proliferative than tumors lacking only Ink4a/Arf (P o0.002) (Figures 3b and d) . Tumor penetrance correlated with mean survival; cohorts with combined Ink4a/Arf and Pten loss displayed the highest penetrance (100%), followed by those with Pten loss (90%) and Ink4a/Arf loss (45%; Figures 2a and 3c ).
EGFR and AXL mediate HBEGF signaling in mouse astrocytes
To determine if HBEGF signals through other RTKs, we performed an unbiased approach using the R&D Proteome Profiler (R&D Systems, Minneapolis, MN, USA), a membrane-based antibody array, which detects phosphorylation of 39 mouse RTK receptors simultaneously. Isogenic astrocytes from Nestin-TVA;Ink4a/Arf lox/lox mice were infected with either RCAS-Cre or RCAS-Cre and RCAS-HBEGF in combination. The cells were serum starved for 24 h, lysed and subjected to the Proteome Profiler immunoassay. As expected, Egfr was phosphorylated in the presence of HBEGF (Figure 4a and Supplementary Figure S3 ). Interestingly, the only other RTK that had a significant increase in phosphorylation in the presence of HBEGF was Axl (Figure 4a and Supplementary Figure S3 ). To ascertain the functional significance of Axl phosphorylation in this context, we used Clustered Regularly-Interspaced Short Palindromic Repeats (CRISPR)-based gene editing to delete Egfr and/or Axl in mouse astrocytes. Guide RNAs specific for mouse Egfr and Axl were designed and expressed in vectors containing resistance genes for blasticidin and puromycin, respectively. Single-cell clones were selected and expanded. Gene editing and loss of expression was confirmed through highresolution melt analysis, sequencing and western blot (Figure 4b ).
Because the guide RNAs are specific for the mouse genome, we performed rescue experiments using the human orthologs of EGFR and AXL. Anchorage-independent growth was assessed by soft-agar assay in this context. Cells lacking either Axl, Egfr or both had significantly fewer colonies than the unmodified parental cells (P o 0.0005; Figure 4c ). Expression of human AXL or EGFR in the corresponding single knockout cells was able to partially rescue the phenotype (P o 0.005; Figure 4c ). In the single knockout cells, endogenous levels of Axl or Egfr are still present, respectively. Therefore, we also performed rescue experiments in cells lacking both Axl and Egfr. Interestingly, EGFR was able to rescue the double knockout cells to the same extent as the corresponding single knockout cells. However, Axl was not able to rescue the double knockout cells to the same extent as the corresponding single knockout cells, suggesting that Egfr is required for activation of Axl in this context (P o0.0005; Figure 4c ). Expression of both AXL and EGFR completely rescued the double knockout cells in the anchorage-independent growth assay ( Figure 4c ).
HBEGF-driven mouse GBM most closely resembles the classical subtype of human GBM Human GBM has been classified into four different subtypes: proneural, classical, mesenchymal and neuronal. 3 High-grade HBEGF-driven tumors in mice resemble human GBM histologically (Figures 3a and 5a ), but it is unclear which subtype, if any, they model. To determine if HBEGF-driven GBM resembled a particular subtype, we generated high-grade gliomas in Nestin-TVA;Ink4a/ Arf lox/lox ;Pten lox/lox mice by delivery of RCAS-Cre and RCAS-HBEGF. In addition, in the same mouse strain, gliomas were generated with RCAS-Cre in combination with RCAS-PDGFA or RCAS-BRAF V600E , other drivers previously found to form high-grade gliomas (Figure 5a ). 19, 23 Previously, gliomas driven by PDGFA in the context of Ink4a/Arf and Pten loss were shown to resemble the proneural subtype using microarray bead chip technology. 23 RNA was extracted from formalin-fixed paraffin-embedded tumor tissue that had been histologically confirmed by a boardcertified neuropathologist (JAS). Three tumors from each cohort along with brain tissue from six control Nestin-TVA-negative Ink4a/Arf lox/lox ;Pten lox/lox mice were analyzed by RNA sequencing from a Ribo-Zero-treated library (Figure 5a and Supplementary Figure S4a ). The transcript coverage and exonic mapping rate were typical for formalin-fixed, paraffin-embedded tissue ( Supplementary Figures S3b and c) . The sample cross-correlation heatmap of the Pearson's correlations shows that each of the tumor replicates clustered with each other and the controls clustered separately from the tumors (Supplementary Figure S4a) . The transcriptome of each cohort was compared with the TCGA GBM subtype classifier genes after converting those genes to their mouse orthologs. The highest correlation for HBEGF was with the classical subtype (r = 0.14), for PDGFA was the proneural subtype (r = 0.30), for BRAF was the mesenchymal subtype (r = 0.47) and for the control was the neural subtype (r = 0.26) as shown on the heatmap (Figure 5b ) and in Supplementary Table S3 . We also performed Gene Set Enrichment Analysis to compare the expression pattern of these tumors with the data sets from the four GBM subgroups as described previously. 24 Based on Gene Set Enrichment Analysis, the transcriptome profile of the HBEGFdriven tumors was a significant match to the signature of the Classical subtype (Supplementary Figure S5a) and was in agreement with the Pearson's correlations (Figure 5b ). As expected, signature gene sets associated with mesenchymal and proneural GBM were significantly enriched in the gene expression profile of BRAF-and PDGFA-driven tumors, respectively (Supplementary Figure S5b and c) .
In both our in vitro and in vivo assays evaluating the oncogenic potential of HBEGF, we did not observe a significant difference with combined overexpression of EGFR (Figures 1b and 2b) . This suggests that endogenous EGFR is sufficient when HEBGF is overexpressed or that an alternative signaling pathway could be possible. The Proteome Profiler and CRISPR-knockout functional studies suggest a role for Axl in HBEGF signaling (Figures 4a and c) . Differential expression analysis in the tumors from RNA sequencing showed specific upregulation of Egfr and Axl transcripts in HBEGF tumors (Supplementary Figure S6) . In PDGFA-driven tumors, there was specific upregulation of Pdgfra (Supplementary Figure S6 ). These results were confirmed with real-time PCR for Axl and Egfr on the same tumor samples ( Figure 5c ). HBEGF-driven tumors had a 10-fold increase in Egfr transcript and 6-fold increase in Axl transcript compared with healthy controls and PDGFA-driven tumors (P o 0.03). HBEGF induced expression of EGFR likely explains why endogenous EGFR was sufficient both in vitro and in vivo.
Suppression of HBEGF expression results in tumor regression and increased survival in vivo
In vitro neutralizing antibodies that recognize HBEGF decrease the proliferation of cultured glioma cells, suggesting that HBEGF is important for tumor cell maintenance. 5, 7, 25 Translating these findings in vivo is complicated by pharmacological limitations in drug kinetics and perfusion across the blood brain barrier. To bypass these limitations, we used a genetic approach to determine whether HBEGF is required for tumor maintenance in vivo. We have previously described the generation of a viral vector that allows expression of inserted genes to be regulated post delivery using the tet-regulated system. 26 A tet-responsive element (TRE) was inserted immediately downstream of the envelope gene in the replication-competent avian retroviral vector RCANBP(A) such that expression of any gene inserted downstream of the TRE was driven from this promoter and not the viral LTR. Expression from the TRE requires the presence of a tetracycline transcriptional activator such as tet-off or a reverse tetracycline transcriptional activator such as tet-on. In the context of tet-on, the tet-responsive gene is expressed only in the presence of doxycycline (Dox); in the context of tet-off, the tet-responsive gene is repressed in the presence of Dox. 27 In the context of tetoff expression in vitro, we observed HBEGF expression that was effectively suppressed by the administration of Dox (Figure 6a ).
Tumors were generated in Nestin-TVA;Ink4a/Arf lox/lox and Nestin-TVA;Pten lox/lox mice with retroviruses containing TRE-HBEGF, tet-off and Cre and confirmed with magnetic resonance imaging (MRI) at 21 days of age. In the Nestin-TVA;Ink4a/Arf lox/lox mice, tumor-bearing mice were split into two cohorts, one receiving standard feed (n = 9) and one receiving Dox feed (n = 10). While the mean survival in the untreated mice was 43.0 ± 7.9 days, the mean survival in the mice treated with Dox was 103.7 ± 4.9 days (P o 0.0001; Figure 6b ). In the Nestin-TVA;Pten lox/lox mice, tumorbearing mice were divided into two cohorts, one receiving standard feed (n = 11) and one receiving Dox feed (n = 15). While the mean survival in the untreated mice was 46.8 ± 6.5 days, all Dox-treated mice survived to the experimental end point of 112 days (P o 0.0001; Figure 6c ). We have previously demonstrated that Dox has no innate tumor-suppressive properties; therefore, tumor regression is due to inhibition of HBEGF expression in this context. 28 Intracranial injection of TRE-HBEGF-, tet-offand Cre-containing retroviruses into newborn Nestin-TVA;Ink4a/Arf lox/lox ;Pten lox/lox mice led to the formation of high-grade tumors in all injected mice (Figure 7a ). To evaluate the kinetics of virally delivered HBEGF expression and activity following Dox treatment, we treated mice with Dox for 3 days. Expression of HBEGF as detected by IHC was visible without Dox treatment; however, following 3 days of Dox treatment very little HBEGF expression was visible by IHC (Figure 7a ). A significant difference was observed in the mean number of cells staining positively for the proliferation marker Ki67 between the mice that received standard Nestin-TVA;Ink4a/Arf lox/lox astrocytes. Human AXL and EGFR were expressed following RCAS-mediated infection for rescue (+). The arrow represents the AXL band. Blots were probed with tubulin antibody as a loading control. (c) Astrocytes from (b) were assayed for soft-agar colony formation to determine the functional significance of Axl and Egfr loss. Data are represented as mean ± s. e.m. Cells lacking either Axl, Egfr or both had significantly fewer colonies than the unmodified parental cells (P o0.0005). Rescue with human AXL or EGFR in the corresponding single knockout cells was significant (P o0.005). There was no significant difference between EGFR rescue in the single versus double knockout cells; however, a significant difference was observed between AXL rescue in the single versus double knockout cells (Po0.0005). Expression of both AXL and EGFR completely rescued the double knockout cells as no significant difference was observed between the double rescue and the control parental cells.
feed and the mice that received Dox feed. While 41.4 ± 4.3 Ki67positive cells were detected per high powered field in the untreated tumor samples, 5.7 ± 1.2 Ki67-positive cells were detected per high powered field in the samples treated with Dox for 3 days (P = 0.002; Figure 7b ).
MRI was performed at 21 days of age to identify tumor-bearing mice and to monitor tumor growth or regression at multiple time points throughout the study. One cohort of tumor-bearing mice received standard feed (n = 16) and the other cohort received Dox feed continuously starting at 21 days of age (n = 10). Survival rates were compared between untreated mice and mice given Dox to determine whether the suppression of HBEGF expression increased survival. While the mean survival in the untreated mice was 23.9 ± 0.8 days, the mean survival in the mice treated starting at 21 days was 83.9 ± 7.7 days (P o0.0001), with one mouse still alive at the experimental end point of 16 weeks (Figure 7c ). This mouse remained tumor free by MRI at 20 weeks of age (Supplementary Figure S7a) . To assess tumor maintenance in more advanced tumors, another cohort received Dox feed starting at 28 days of age (n = 10; Figure 7c ). The mean survival in the mice treated starting at 28 days was 62.0 ± 7.5 days, which was significantly different from the untreated mice (P o 0.0001). However, the mice treated at 28 days had significantly reduced mean survival compared with the mice treated at 21 days (P = 0.02), demonstrating that earlier treatment increases survival.
Recurrent tumors develop in the absence of HBEGF expression in the context of Ink4a/Arf and Pten loss Tumors recurred in 19/20 responding Nestin-TVA;Ink4a/Arf lox/lox ; Pten lox/lox mice while on Dox treatment. The MRI data from a representative mouse that developed recurrent disease while on Dox treatment is shown in Supplementary Figure S7b . A small tumor is visible pre-Dox treatment but no tumor was visible at 28, 42 or 64 days; however, tumor recurrence was visible starting at 84 days and a large recurrent tumor was detected at 104 days. Brain tissue was examined and H&E analysis confirmed GBM in this mouse. Of evaluable mice with recurrent tumors, 50% expressed HBEGF and 50% recurred in the absence of HBEGF expression (Figure 7d and Supplementary Figure S8 ). Expression of PDGFRA, AXL, EGFR and MET was also evaluated by IHC in these tumors (Supplementary Figure S9) . Interestingly, EGFR expression was not detected in any of the recurrent tumors. In contrast, PDGFRA was detected in 9/10 recurrent tumors, AXL was detected in 7/10 recurrent tumors and MET was detected in 3/10 recurrent tumors. Future studies will evaluate which of these RTKs, if any, mediate resistance in this context.
DISCUSSION
Using an established mouse model of glioma, 19 we assessed the sufficiency of HBEGF in gliomagenesis. While not sufficient on its own, HBEGF cooperates with Ink4a/Arf or Pten loss to promote gliomagenesis. To our knowledge, this is the first report showing that HBEGF can lead to malignant glioma development in this context. Comparison of these HBEGF tumors to the human subtype signatures show that while they positively correlated with the neural, pronerual and classical signatures, the strongest correlation was with the classical subtype. 3 We also show that previously published mouse models for PDGFA and BRAF V600E resemble the proneural and mesenchymal subtypes, respectively. 3, 19, 23 We have observed that in astrocytes in vitro, HBEGF activates not only Egfr but also Axl, a member of the TAM family of RTKs. AXL has been shown to be upregulated in human glioma cell lines and tissue, but activation of AXL in the presence of HBEGF has not previously been reported in gliomas or other cancers. 17, 18 Although unreported in the context of HBEGF, a role for AXL in mediating EGFR signaling has been cited as a mechanism of resistance against targeted EGFR therapies in lung and breast cancer. 29, 30 In breast cancer cells, the two receptors were found to physically interact. In addition, while activation of EGFR through the addition of EGF transactivated AXL in this context, the addition of an AXL-activating antibody did not phosphorylate EGFR. 31 It is therefore possible that HBEGF activates AXL via transactivation from an activated EGFR receptor.
While determination of the initial events in the genesis of a glioma are biologically important, it is perhaps more important clinically to ascertain the conditions for tumor maintenance to help guide clinical intervention. As an initial step toward developing targeted therapies, we used a tetracycline-regulated system to control HBEGF expression to assess the necessity of HBEGF in sustaining tumor growth. We demonstrated increased mean survival in all cohorts of mice after inhibition of HBEGF. While half of the recurrent tumors in the Nestin-TVA;Ink4a/Arf lox/lox ; Pten lox/lox mice expressed HBEGF, half recurred in the absence of HBEGF expression. While EGFR expression was not detected in these recurrent tumors, several other RTKs were expressed. Pathway crosstalk and signaling redundancies have been implicated in mediated drug resistance in several cancers, including gliomas. Future studies will evaluate the mechanism(s) of resistance in these tumors. Our study suggests that HBEGF promotes the formation of gliomas, is necessary for tumor maintenance and therefore may be a novel therapeutic target.
MATERIALS AND METHODS
Mice and Genotyping
Nestin-TVA;Ink4a/Arf lox/lox ;Pten lox/lox mice were generated from pre-existing strains. PCR for the TVA transgene and for the Ink4a/Arf lox , wild-type Ink4a/ Arf, Pten lox and wild-type Pten alleles was performed as described previously. 32 All experiments were IACUC approved before experimentation.
Gene editing
Astrocytes were established as described previously. 33 To disrupt Egfr and Axl via CRISPR-based gene editing, astrocytes were infected with VSV-Gpseudotyped plenti-CRISPRv2-Egfr (target: 5′-CCTCCATTAGACCATCCAG G-3′) containing blasticidin resistance and/or plenti-CRISPRv2-Axl (target: 5′-CAGGTGCCAGAGGACTCACG-3′) containing puromycin resistance. 34 Clones were selected using 2.5 μg/ml puromycin and/or 80 μg/ml blasticidin, screened with high-resolution melt analysis and confirmed with Sanger sequencing followed by western blot analysis. 35 
Viral constructs
The RCAS-Cre and RCAS-tet-off avian retroviral vectors and RCAS-BRAF V600E have been described previously. 19, 20 Cloning details for RCAS-HBEGF and RCAN-TRE-HBEGF are available upon request. Virus was propagated and in vitro infections were carried out as described previously. 33 
Soft-agar assay
To assess anchorage-independent growth, cells were assayed in triplicate as described previously and visualized with 1 μg/μl nitroblue tetrazolium stain (Invitrogen, Carlsbad, CA, USA) added 200 μl overnight. 19, 33 Western blotting Protein quantification and immunostaining were carried out as described previously. 33 Antibodies used are available upon request.
R&D Proteome Profiler RTK Array
Astrocytes were serum-starved overnight and then analyzed using the Proteome Profiler Mouse Phospho-RTK Array Kit (R&D Systems) following the manufacturer's instructions. 
In vivo infection
Newborn mice were injected intracranially 2 mm ventral from bregma as described previously. 19, 36 Histological analysis Brain tissue from injected mice was fixed, embedded, stained and imaged as described previously. 33 Bioinformatics and genomics TCGA GBM data were accessed through cBioPortal (New York, NY, USA). 37, 38 GBM classifier genes were converted to mouse orthologues using Biomart (Toronto, ON, Canada). 3, 23 RNA was isolated using the Recoverall Kit (Ambion, Austin, TX, USA), prepped with TruSeq Stranded Total RNA using Ribo-Zero Gold and sequenced with HiSeq 50-Cycle Single-Read Sequencing v.4 (Illumina, San Diego, CA, USA). Reads were aligned to the mouse genome (mm10) and differential gene expression was determined with the open source USeq/DESeq2 package. Genes were selected using two thresholds, a false discovery rate of o10% and absolute log 2 ratio41. Tumor and control variance normalized expression data (r log values) was converted to median centered log 2-fold change and compared with the TCGA classifier genes using pairwise Pearson's correlations. Gene Set Enrichment Analysis (v.2.2.0) was used to analyze the enrichment of signature gene sets from different GBM subtypes as described. 24 Immunohistochemistry Tissue sections were immunostained as described previously. 19, 33 Antibodies used are available upon request.
Magnetic resonance imaging
Mice were anesthetized and imaged as described previously. 20, 28 
Statistical analysis
Western blot and RTK arrays were performed in triplicate and duplicate, respectively, and density was analyzed using Image J (NIH, Bethesda, MD, USA). Survival data (n49) was analyzed using a log-rank test of the Figure 7 . Suppression of HBEGF expression prolongs survival in vivo. (a) Immunohistochemical analysis of HBEGF and Ki67 in brain tissue isolated from Nestin-TVA;Ink4a/Arf lox/lox ;Pten lox/lox mice injected with RCAN-TRE-HBEGF, RCAS-tet-off and RCAS-Cre that were either untreated or treated with Dox for 3 days after being weaned at 21 days of age. The two samples are from the same timepoint of 3 days. Scale bar, 300 μm. (b) The Ki67 staining was quantified using two representative tumors for each cohort. For each tumor, the average of four high-power fields is shown. Data are represented as mean ± s.e.m. (**Po 0.005). (c) Kaplan-Meier survival analysis of Nestin-TVA;Ink4a/Arf lox/lox ;Pten lox/lox injected with RCAN-TRE-HBEGF, RCAS-tet-off and RCAS-Cre that were not treated (n = 16, round dash), treated starting at 21 days of age (n = 10, solid line) or treated starting at 28 days of age (n = 10, short dash). The Dox-treated cohorts were compared with the untreated cohort (***P o0.0005). (d) Immunohistochemical analysis of regressed tumors using antibodies against HBEGF and Ki67 with corresponding H&E. Scale bar, 300 μm. Both regressed tumors are from two different mice that were treated for 30 days with Dox.
